Search results
Sep 2, 2020 · These studies suggest a link between COVID-19 and GBS. At the time of writing this paper, approximately 31 cases of GBS associated with COVID-19 infection have been reported. This study showed that, on average, 11.92 ± 6.20 days after COVID-19 infection, the neurological symptoms of GBS begin.
Jan 17, 2023 · In recent months, a variety of studies and case reports have proposed an association between COVID-19 and Guillain–Barré syndrome (GBS). The present work aims to systematically review the publications available to date to verify the relationship between these two pathologies and the characteristics of post-COVID GBS.
Feb 1, 2023 · Among US (domestic) VAERS reports submitted from December 14, 2020, through January 28, 2022, for people ages 18 years and older who received a COVID-19 vaccine (Ad26.COV2.S, BNT162b2, or mRNA-1273), we searched for the following MedDRA PTs: acute motor axonal neuropathy, acute motor-sensory axonal neuropathy, autoimmune neuropathy ...
Guillain-Barré syndrome (GBS), an immune-mediated polyradiculoneuropathy with a ≈5% mortality rate, has an incidence worldwide of 0.81–1.91 cases/100,000 person-years ( 1 ). GBS has been reported to be associated with coronavirus disease (COVID-19) vaccination, but a comprehensive summary regarding this rare adverse event is still lacking.
Apr 17, 2020 · Five patients who had Guillain–Barré syndrome 5 to 10 days after the onset of Covid-19 are described. Three had severe weakness and an axonal pattern on electrophysiological studies, and...
Sep 7, 2021 · COVID-19–related Guillain-Barré syndrome (GBS) is of particular importance given its association with higher mortality rates and prolonged respiratory failure. Review Summary: We conducted a systematic review of published cases for COVID-19–related GBS, and provide a summary of clinical management strategies for these cases.
Jan 23, 2023 · The GBS symptoms began on average 19 days after the onset of COVID-19 infection. Regarding GBS, the main manifestations found included generalized weakness, reflex reduction, facial paresis/paralysis and hypoesthesia. As expected, the most common result in cerebrospinal fluid (CSF) analysis was albuminocytological dissociation.
